Last updated on August 2019

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD


Brief description of study

This is a multicenter, randomized, double-blind, placebo-controlled, 30-week, adaptive cross-over study, with a Treatment Period of approximately 26 weeks under the Original Design or, if applicable, a 17-week parallel study, with a Treatment Period of approximately 14 weeks under the Contingent Design.

Clinical Study Identifier: NCT03496623

Find a site near you

Start Over

CardioPulmonary Research Center

Guaynabo, Puerto Rico
5.52miles
  Connect »